2-[[3-Cyclohexyl-1-[2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid (BioDeep_00000175624)
human metabolite blood metabolite
代谢物信息卡片
化学式: C21H38N6O4 (438.2954)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 79.35%
分子结构信息
SMILES: C1CCC(CC1)CC(C(=O)N2CCCCC2C(=O)NCCCN=C(N)N)NCC(=O)O
InChI: InChI=1S/C21H38N6O4/c22-21(23)25-11-6-10-24-19(30)17-9-4-5-12-27(17)20(31)16(26-14-18(28)29)13-15-7-2-1-3-8-15/h15-17,26H,1-14H2,(H,24,30)(H,28,29)(H4,22,23,25)
描述信息
同义名列表
6 个代谢物同义名
2-({3-cyclohexyl-1-[2-({3-[(diaminomethylidene)amino]propyl}carbamoyl)piperidin-1-yl]-1-oxopropan-2-yl}amino)acetic acid; ({3-cyclohexyl-1-[2-({3-[(diaminomethylidene)amino]propyl}carbamoyl)piperidin-1-yl]-1-oxopropan-2-yl}amino)acetic acid; 2-[[3-Cyclohexyl-1-[2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid; N-(2-(2-(((3-((Aminoiminomethyl)amino)propyl)amino)carbonyl)-1-piperidinyl)-1-(cyclohexylmethyl)-2-oxo-ethyl)glycine; 2-[[3-Cyclohexyl-1-[2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetate; Inogatran
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Alexey Poyarkov, Xavier Rocabayera, Svetlana Poyarkova, Valery Kukhar. Influence of aromatic and aliphatic moieties on thrombin inhibitors potency.
The open biochemistry journal.
2008; 2(?):143-9. doi:
10.2174/1874091x00802010143. [PMID: 19238188] - Giuseppe Leone, Elena Rossi, Antonio Maria Leone, Valerio De Stefano. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
Current medicinal chemistry. Cardiovascular and hematological agents.
2004 Oct; 2(4):311-26. doi:
10.2174/1568016043356183. [PMID: 15320782] - Judith Leurs, Britt-Marie Wissing, Viveca Nerme, Katinka Schatteman, Petter Björquist, Dirk Hendriks. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.
Thrombosis and haemostasis.
2003 Feb; 89(2):264-71. doi:
10.1055/s-0037-1613441. [PMID: 12574805] - Rikard Linder, Siw Frebelius, Katarina Jansson, Jesper Swedenborg. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
2003 Feb; 14(2):139-46. doi:
10.1097/00001721-200302000-00004. [PMID: 12632023] - J Hauptmann. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors.
European journal of clinical pharmacology.
2002 Jan; 57(11):751-8. doi:
10.1007/s00228-001-0392-7. [PMID: 11868795] - C Mattsson, A Menschik-Lundin, S Nylander, E Gyzander, J Deinum. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro.
Thrombosis research.
2001 Dec; 104(6):475-86. doi:
10.1016/s0049-3848(01)00392-9. [PMID: 11755958] - M Cullberg, U G Eriksson, M Larsson, M O Karlsson. Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.
British journal of clinical pharmacology.
2001 Jan; 51(1):71-9. doi:
10.1046/j.1365-2125.2001.01326.x. [PMID: 11167667] - R Linder, M Blombäck, N Egberg, L Grip. Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C.
Thrombosis research.
1999 Jul; 95(2):117-25. doi:
10.1016/s0049-3848(99)00029-8. [PMID: 10418800] - C D Finkle, A St Pierre, L Leblond, I Deschenes, J DiMaio, P D Winocour. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Thrombosis and haemostasis.
1998 Feb; 79(2):431-8. doi:
10.1055/s-0037-1615003. [PMID: 9493603] - U G Eriksson, L Renberg, U Bredberg, A C Teger-Nilsson, C G Regårdh. Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug.
Biopharmaceutics & drug disposition.
1998 Jan; 19(1):55-64. doi:
10.1002/(sici)1099-081x(199801)19:1<55::aid-bdd74>3.0.co;2-h. [PMID: 9510985] - M Elg, D Gustafsson, J Deinum. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Thrombosis and haemostasis.
1997 Oct; 78(4):1286-92. doi:
10.1055/s-0038-1657729. [PMID: 9364999] - NULL. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
European heart journal.
1997 Sep; 18(9):1416-25. doi:
10.1093/oxfordjournals.eurheartj.a015467. [PMID: 9458447] - A C Teger-Nilsson, R Bylund, D Gustafsson, E Gyzander, U Eriksson. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor.
Thrombosis research.
1997 Jan; 85(2):133-45. doi:
10.1016/s0049-3848(96)00230-7. [PMID: 9058487] - K Andersen, M Dellborg, H Emanuelsson, L Grip, K Swedberg. Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment.
Coronary artery disease.
1996 Sep; 7(9):673-81. doi:
10.1097/00019501-199609000-00009. [PMID: 8950498] - D Gustafsson, M Elg, S Lenfors, I Börjesson, A C Teger-Nilsson. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
1996 Jan; 7(1):69-79. doi:
10.1097/00001721-199601000-00009. [PMID: 8845466]
